Table 3.

Overall survival in patients with metastatic castrate-resistant prostate cancer who were treated with vaccines or other therapeutic modalities^*

Agent	Type of therapy	Stop treatment AE, %	Improvement in median OS, mo	Hazard ratio	Reduction in death rate, %
Docetaxel	Chemotherapy	11	2.4	0.76	24
Cabazitaxel	Chemotherapy	18	2.4	0.70	30
Abiraterone	Hormone	19	3.9	0.66	34
Sipuleucel-T	Vaccine	1.5	4.1	0.78	22
PROSTVAC†	Vaccine	∼2	8.5	0.56	44

^*AE = adverse event; OS = overall survival; PROSTVAC = a recombinant vaccinia virus priming vaccination and multiple fowlpox booster vaccinations. Each vector contains transgenes for prostate-specific antigen and three costimulatory molecules (CD80, intercellular adhesion molecule 1, and lymphocyte function–associated antigen 3) that are collectively designated TRICOM.

^†Results of a 43-center randomized placebo-controlled phase II trial.